Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Modulation of sphingosine 1-phosphate (S1P) receptors in a non-selective manner decreases disease activity in patients with multiple sclerosis but has potential safety concerns. We assessed the safety and efficacy of the oral selective S1P receptor modulator ozanimod in patients with relapsing multiple sclerosis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Neurol

Title: The Lancet. Neurology

Publisher: Elsevier BV

ISSN (Electronic): 1474-4465

ISSN (Print): 1474-4422

Publication date (Electronic): Apr 2016

Volume: 15

Issue: 4

Affiliations

[1 ] Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA. Electronic address: cohenj@ccf.org.

[2 ] NeuroRx Research and Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.

[3 ] San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Neurology, Milan, Italy.

[4 ] Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.

[5 ] Receptos Inc, Clinical Development, San Diego, CA, USA.

[6 ] Neurology Center, Lodz, Poland.

Article

Publisher Item ID: S1474-4422(16)00018-1

DOI: 10.1016/S1474-4422(16)00018-1

PubMed ID: 26879276

SO-VID: b370723f-3498-429a-a4f6-444872ed53be

History

Data availability:

Comments

Comment on this article

scite_

Cited by 61

See all cited by

- Version 1